Evidence map›Paper›PMID 33558888›Full record

ArticleBioscience reports2021

Dexmedetomidine attenuates lipopolysaccharide-induced acute liver injury in rats by inhibiting caveolin-1 downstream signaling pathway.

Fei Tong, Wenchao Shen, Pengtao Song, Jiafeng Song, Yonghe Hu, Feifan Liu, Zhipeng Meng, Jing Liu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Clinical Use of Adrenergic Receptor Ligands in Acute Care Settings.Handbook of experimental pharmacology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Role of Caveolin-1 in Sepsis - A Mini-Review.Frontiers in immunology · 2022
    Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fei Tong *Department of Anesthesiology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Wenchao Shen *Department of Radiology, Huzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
Pengtao SongDepartment of Pathology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Jiafeng SongDepartment of Pathology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Yonghe HuDepartment of Anesthesiology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Feifan LiuDepartment of Anesthesiology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Zhipeng MengDepartment of Anesthesiology, Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, Zhejiang Province, China.
Jing LiuDepartment of Anesthesiology, Huzhou Maternal and Child Health Care Hospital, Huzhou, Zhejiang Province, China.
Huzhou Central Hospital · CNHuzhou Women and Children's Hospital · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the present study is to investigate the anti-injury and anti-inflammatory effects of dexmedetomidine (Dex) in acute liver injury induced by lipopolysaccharide (LPS) in Sprague-Dawley rats and its possible mechanism.

methodsThe acute liver injury model of male rats was established by injecting LPS into tail vein. The mean arterial pressure (MAP) of rats was recorded at 0-7 h, and lactic acid was detected at different time points. Wet/dry weight ratio (W/D) was calculated. Pathological changes of rat liver were observed by HE staining. ALT and AST levels in serum were detected. The activities of myeloperoxidase (MPO) and superoxide dismutase (SOD) in liver tissue homogenate and the levels of IL-1β and IL-18 in serum were detected by ELISA. Protein levels of Caveolin-1 (Cav-1), TLR-4 and NLRP3 in liver tissue were tested by immunohistochemistry method. The expression of Cav-1, TLR-4 and NLRP3 mRNA in liver tissue was detected by quantitative polymerase chain reaction (qPCR) to explore its related mechanism.

resultsCompared with NS group, serum lactic acid, W/D of liver tissue, MPO, SOD, IL-1β and IL-18 were significantly increased and MAP decreased significantly in LPS group and D+L group. However, compared with NS group, D group showed no significant difference in various indicators. Compared with LPS group, MPO, SOD, IL-1β and IL-18 were significantly decreased and MAP was significantly increased in D+L group. D+L group could significantly increase the level of Cav-1 protein and decrease the level of TLR-4 and NLRP3 protein in liver tissue caused by sepsis. The expression of Cav-1 mRNA was significantly up-regulated and the expression of TLR-4 and NLRP3 mRNA was inhibited in D+L group.

conclusionDex pretreatment protects against LPS-induced actue liver injury via inhibiting the activation of the NLRP3 signaling pathway by up-regulating the expression of Cav-1 by sepsis.

Indexed as

Signal TransductionAnimalsAnti-Inflammatory AgentsCaveolin 1DexmedetomidineInterleukinsLipopolysaccharidesLiverLiver Failure, AcuteMaleNLR Family, Pyrin Domain-Containing 3 ProteinRatsRats, Sprague-DawleyToll-Like Receptor 4Anti-Inflammatory AgentsCaveolin 1DexmedetomidineInterleukinsLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratTlr4 protein, ratToll-Like Receptor 4Acute liver injuryDexmedetomidineLipopolysaccharideNLRP3TLR-4

Identifiers

PMID33558888
PMCPMC7938455
OpenAlexW3127698804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.